Webb24 aug. 2024 · (Shape Photo) Shape Therapeutics has signed a deal potentially exceeding $3 billion with pharma giant Roche to support the development of gene therapies for Alzheimer’s and Parkinson’s... WebbPioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases Our Story Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the goal of developing novel gene therapy …
RSLS Stock Price ReShape Lifesciences Inc. Stock Quote (U.S.: …
WebbShapeTX Stock shapetx.com Healthcare Founded: 2024 Funding to Date: $138.25MM Shape Therapeutics is a biotechnology company focused on developing breakthrough RNA technologies to shape the future of gene therapy. Buy or sell ShapeTX stock Learn more about ShapeTX IPO Register for Details WebbThe Shield Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 6.44p. The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share. pdcss princeton
Roche : Shape Therapeutics enters into a strategic research ...
WebbFunding. Shape Therapeutics has raised a total of $147.5M in funding over 2 rounds. Their latest funding was raised on Jul 15, 2024 from a Series B round. Shape Therapeutics is funded by 8 investors. New Enterprise Associates … WebbThe ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, … Webb9 nov. 2024 · The startups have collectively raised more than $320 million, although ReCode and Shape are also working on other RNA-based technologies. Tevard and … scuba steve dive shop tyler tx swim lessons